Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+ locoregionally advanced oropharyngeal cancer (OPC).

Trial Details

NCT ID
NCT07290621
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Toripalimab
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Subjects must have pathologically confirmed HPV16-positive head and neck squamous cell carcinoma of the oropharynx. Confirmed HPV-positive disease …
  • HPV16 subtype demonstrated based on the following guidelines:
  • p16 IHC positivity is sufficient to enroll and initiate treatment (p16 IHC interpretation to follow guidelines by Jordan and Lingen et al72).
  • HPV PCR must demonstrate HPV16 subtype.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →